3-{[4-(2-ethoxyphenyl)-piperazin-1-yl]methyl}-1H-indole | 414882-56-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-{[4-(2-ethoxyphenyl)-piperazin-1-yl]methyl}-1H-indole
• 英文别名: 3-[[4-(2-ethoxyphenyl)piperazin-1-yl]methyl]-1H-indole
• CAS: 414882-56-7
• 化学式: C₂₁H₂₅N₃O
• 分子量: 335.449
• InChiKey: PFALMGBZVKYODL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  31.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吲哚 、 聚合甲醛 、 1-(2-乙氧基苯基)哌嗪 以 溶剂黄146 为溶剂， 反应 1.0h， 以66%的产率得到3-{[4-(2-ethoxyphenyl)-piperazin-1-yl]methyl}-1H-indole
  参考文献：
  名称：

  通过交互式SAR研究发现强效和选择性D4配体

  摘要：

  合成了一系列噻吩甲基苯基哌嗪并测试了其对五种多巴胺能受体亚型的亲和力。化合物5f对D4受体显示出超过1000倍的选择性。类似物5e显示出对K i 3.9 nM的D4受体的最高亲和力。采用了交互式SAR方法，导致化合物14a的K i（D4）低至0.03 nM。分子对接研究表明，有潜力首先报道D4独特残基Arg-186与配体芳烃部分之间的芳烃阳离子相互作用，这说明在化合物结构的这一区域具有强的负静电势的重要性。

  DOI：

  10.1016/j.bmcl.2013.07.033

文献信息

• 5HT7 receptor ligands and compositions comprising the same
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2149373A1

  公开（公告）日：2010-02-03

  The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a disease in which 5-HT7 is involved, such as CNS disorders.

  本发明涉及具有药理活性的化合物，特别是作为5-HT7受体激动剂，通过使用药效团和描述符的配置文件筛选识别，以及包含它们的药物组合物。这些化合物在治疗中特别有用，特别是用于治疗和/或预防涉及5-HT7的疾病，如中枢神经系统紊乱。
• Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2151777A1

  公开（公告）日：2010-02-10

  The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor; to a method for identifying them as 5-HT7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT7 is involved, such as CNS disorders.

  本发明涉及对5-HT7受体具有药理活性的化合物；涉及通过使用药效谱和描述符特征过滤器将它们鉴定为5-HT7配体，特别是激动剂的方法；涉及包含它们的药物组合物；涉及它们在治疗中的用途，特别是用于治疗和预防5-HT7参与的疾病，如中枢神经系统疾病。
• METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER
  申请人：Pascual-Ramon Rosalia

  公开号：US20110124657A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor; to a method for identifying them as 5-HT 7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
• 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME
  申请人：Pascual-Ramon Rosalia

  公开号：US20110183991A1

  公开（公告）日：2011-07-28

  The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
• Discovery of highly potent and selective D4 ligands by interactive SAR study
  作者：Mohamed A.O. Abdelfattah、Jochen Lehmann、Ashraf H. Abadi

  DOI：10.1016/j.bmcl.2013.07.033

  日期：2013.9

  5f showed more than 1000 folds selectivity to D4 receptors; analogue 5e showed the highest affinity to D4 receptors with Ki 3.9 nM. An interactive SAR approach was adopted and lead to compound 14a with Ki (D4) as low as 0.03 nM. Molecular docking studies showed a potential, first to report arene cation interaction between the D4 unique residue Arg-186 and the ligands’ arene moiety, explaining the importance

  合成了一系列噻吩甲基苯基哌嗪并测试了其对五种多巴胺能受体亚型的亲和力。化合物5f对D4受体显示出超过1000倍的选择性。类似物5e显示出对K i 3.9 nM的D4受体的最高亲和力。采用了交互式SAR方法，导致化合物14a的K i（D4）低至0.03 nM。分子对接研究表明，有潜力首先报道D4独特残基Arg-186与配体芳烃部分之间的芳烃阳离子相互作用，这说明在化合物结构的这一区域具有强的负静电势的重要性。